Skip to main content
SpringerLink
Log in

Immune Dysregulation Diseases

  • Chapter
  • First Online:
Clinical Cases in Primary Immunodeficiency Diseases

  • 1141 Accesses

Abstract

The main task of immune system is to protect the body against infections. When an antigen is recognized as a nonself by the immune system, a highly dynamic cascade of reactions will begin which includes both innate and adaptive immune responses. These mechanisms should be firmly controlled because exaggerated response to foreign antigens and/or improper response against self-antigens can result in autoimmunity. Various cells and mediator molecules are involved in the regulation of immune system. The complexity of this system makes it prone to many genetic defects resulting in increased susceptibility to infections and/or autoimmune disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torgerson TR (2008) Immune dysregulation in primary immunodeficiency disorders. Immunol Allergy Clin North Am 28(2):315–327, viii–ix

    Article  PubMed  Google Scholar 

  2. Halonen M, Eskelin P, Myhre AG, Perheentupa J, Husebye ES, Kampe O, Rorsman F, Peltonen L, Ulmanen I, Partanen J (2002) AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab 87(6):2568–2574

    Article  PubMed  CAS  Google Scholar 

  3. Torgerson TR, Ochs HD (2007) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 120(4):744–750, quiz 751–742

    Article  PubMed  CAS  Google Scholar 

  4. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Basile Saint G, Kumar V (1999) Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286(5446):1957–1959

    Article  PubMed  CAS  Google Scholar 

  5. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, Lambert N, Ouachee-Chardin M, Chedeville G, Tamary H, Minard-Colin V, Vilmer E, Blanche S, Le Deist F, Fischer A, de Basile Saint G (2003) Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115(4):461–473

    Article  PubMed  CAS  Google Scholar 

  6. Zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, Kabisch H, Schneppenheim R, Nurnberg P, Janka G, Hennies HC (2005) Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 14(6):827–834

    Article  PubMed  CAS  Google Scholar 

  7. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH (2011) Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial hemophagocytic lymphohistiocytosis. Blood 118(22):5794–8, Epub 2011 Aug 31

    Article  PubMed  CAS  Google Scholar 

  8. Ward DM, Shiflett SL, Kaplan J (2002) Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr Mol Med 2(5):469–477

    Article  PubMed  CAS  Google Scholar 

  9. Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le Deist F, de Basile Saint G (2000) Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 25(2):173–176

    Article  PubMed  CAS  Google Scholar 

  10. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, Kontny U, Muller C, Nurden A, Rohr J, Henschen M, Pannicke U, Niemeyer C, Nurden P, Ehl S (2006) Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 108(1):81–87

    Article  PubMed  CAS  Google Scholar 

  11. Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van Loon A, Griffith J, Krijgsveld J, Wulffraat N, Koch H, Heck AJ, Brose N, Kleijmeer M, van der Sluijs P (2005) Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 16(2):731–741

    Article  PubMed  CAS  Google Scholar 

  12. Menager MM, Menasche G, Romao M, Knapnougel P, Ho CH, Garfa M, Raposo G, Feldmann J, Fischer A, de Basile Saint G (2007) Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol 8(3):257–267

    Article  PubMed  CAS  Google Scholar 

  13. Wei ML (2006) Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res 19(1):19–42

    Article  PubMed  CAS  Google Scholar 

  14. Cullinane AR, Curry JA, Carmona-Rivera C, Summers CG, Ciccone C, Cardillo ND, Dorward H, Hess RA, White JG, Adams D, Huizing M, Gahl WA (2011) A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak syndrome type 9. Am J Hum Genet 88(6):778–787

    Article  PubMed  CAS  Google Scholar 

  15. Bohn G, Welte K, Klein C (2007) Severe congenital neutropenia: new genes explain an old disease. Curr Opin Rheumatol 19(6):644–650

    Article  PubMed  Google Scholar 

  16. Thielen N, Huizing M, Krabbe JG, White JG, Jansen TJ, Merle PA, Gahl WA, Zweegman S (2010) Hermansky-Pudlak syndrome: the importance of molecular subtyping. J Thromb Haemost 8(7):1643–1645

    Article  PubMed  CAS  Google Scholar 

  17. Jung J, Bohn G, Allroth A, Boztug K, Brandes G, Sandrock I, Schaffer AA, Rathinam C, Kollner I, Beger C, Schilke R, Welte K, Grimbacher B, Klein C (2006) Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood 108(1):362–369

    Article  PubMed  CAS  Google Scholar 

  18. Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, Bossi G, Hamblin T, Davies EG, Griffiths GM (2003) Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 4(11):1111–1120

    Article  PubMed  CAS  Google Scholar 

  19. Fontana S, Parolini S, Vermi W, Booth S, Gallo F, Donini M, Benassi M, Gentili F, Ferrari D, Notarangelo LD, Cavadini P, Marcenaro E, Dusi S, Cassatella M, Facchetti F, Griffiths GM, Moretta A, Badolato R (2006) Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood 107(12):4857–4864

    Article  PubMed  CAS  Google Scholar 

  20. Badolato R, Parolini S (2007) Novel insights from adaptor protein 3 complex deficiency. J Allergy Clin Immunol 120(4):735–741, quiz 742–743

    Article  PubMed  CAS  Google Scholar 

  21. Rozenszajn LA, David EB, Sela SB (1977) Large granules and lysosomal fusion in human Chediak-Higashi white blood cells. Acta Haematol 57(5):279–289

    Article  PubMed  CAS  Google Scholar 

  22. Rubin CM, Burke BA, McKenna RW, McClain KL, White JG, Nesbit ME Jr, Filipovich AH (1985) The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 56(3):524–530

    Article  PubMed  CAS  Google Scholar 

  23. Trottestam H, Beutel K, Meeths M, Carlsen N, Heilmann C, Pasic S, Webb D, Hasle H, Henter JI (2009) Treatment of the X-linked lymphoproliferative, Griscelli and Chediak-Higashi syndromes by HLH directed therapy. Pediatr Blood Cancer 52(2):268–272

    Article  PubMed  Google Scholar 

  24. Henter JI, Elinder G, Ost A (1991) Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 18(1):29–33

    PubMed  CAS  Google Scholar 

  25. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131

    Article  PubMed  Google Scholar 

  26. Imashuku S (2000) Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol 72(1):1–11

    PubMed  CAS  Google Scholar 

  27. Janka GE, Schneider EM (2004) Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 124(1):4–14

    Article  PubMed  Google Scholar 

  28. Janka GE (2007) Hemophagocytic syndromes. Blood Rev 21(5):245–253

    Article  PubMed  CAS  Google Scholar 

  29. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI (1998) Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 12(2):435–444

    Article  PubMed  CAS  Google Scholar 

  30. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, Yamamoto K, Horiuchi H, Takada K, Ohshima K, Nakamura S, Kinukawa N, Oshimi K, Kawa K (2007) Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86(1):58–65

    Article  PubMed  Google Scholar 

  31. Cetica V, Pende D, Griffiths GM, Arico M (2010) Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica 95(4):538–541

    Article  PubMed  CAS  Google Scholar 

  32. Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, Heath PT, Steward CG, Smith O, O’Meara A, Kerrigan H, Mahlaoui N, Cavazzana-Calvo M, Fischer A, Moshous D, Blanche S, Pachlopnick-Schmid J, Latour S, de Saint-Basile G, Albert M, Notheis G, Rieber N, Strahm B, Ritterbusch H, Lankester A, Hartwig NG, Meyts I, Plebani A, Soresina A, Finocchi A, Pignata C, Cirillo E, Bonanomi S, Peters C, Kalwak K, Pasic S, Sedlacek P, Jazbec J, Kanegane H, Nichols KE, Hanson IC, Kapoor N, Haddad E, Cowan M, Choo S, Smart J, Arkwright PD, Gaspar HB (2011) X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117(1):53–62

    Article  PubMed  CAS  Google Scholar 

  33. Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH (2010) XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 116(7):1079–1082

    Article  PubMed  CAS  Google Scholar 

  34. Ueda I, Ishii E, Morimoto A, Ohga S, Sako M, Imashuku S (2006) Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr Blood Cancer 46(4):482–488

    Article  PubMed  Google Scholar 

  35. Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Arico M, Moretta L, Pende D (2006) Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 108(7):2316–2323

    Article  PubMed  CAS  Google Scholar 

  36. Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, Almazan F, Boelens JJ, Hasle H, Ifversen M, Lund B, van den Berg JM, Gustafsson B, Hjelmqvist H, Nordenskjold M, Bryceson YT, Henter JI (2010) Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood 116(15):2635–2643

    Article  PubMed  CAS  Google Scholar 

  37. Ueda I, Kurokawa Y, Koike K, Ito S, Sakata A, Matsumora T, Fukushima T, Morimoto A, Ishii E, Imashuku S (2007) Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol 82(6):427–432

    Article  PubMed  CAS  Google Scholar 

  38. Rudd E, Bryceson YT, Zheng C, Edner J, Wood SM, Ramme K, Gavhed S, Gurgey A, Hellebostad M, Bechensteen AG, Ljunggren HG, Fadeel B, Nordenskjold M, Henter JI (2008) Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis. J Med Genet 45(3):134–141

    Article  PubMed  CAS  Google Scholar 

  39. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, Bechensteen AG, Boelens JJ, Celkan T, Farah RA, Hultenby K, Winiarski J, Roche PA, Nordenskjold M, Henter JI, Long EO, Ljunggren HG (2007) Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 110(6):1906–1915

    Article  PubMed  CAS  Google Scholar 

  40. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE (2011) Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol 127(6):1329–1341.e1322, quiz 1342–1343

    Article  PubMed  Google Scholar 

  41. Gismondi A, Cifaldi L, Mazza C, Giliani S, Parolini S, Morrone S, Jacobelli J, Bandiera E, Notarangelo L, Santoni A (2004) Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 104(2):436–443

    Article  PubMed  CAS  Google Scholar 

  42. Argov S, Johnson DR, Collins M, Koren HS, Lipscomb H, Purtilo DT (1986) Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome. Cell Immunol 100(1):1–9

    Article  PubMed  CAS  Google Scholar 

  43. Endt J, Eissmann P, Hoffmann SC, Meinke S, Giese T, Watzl C (2007) Modulation of 2B4 (CD244) activity and regulated SAP expression in human NK cells. Eur J Immunol 37(1):193–198

    Article  PubMed  CAS  Google Scholar 

  44. Katz P, Zaytoun AM, Fauci AS (1982) Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. J Clin Invest 69(6):1231–1238

    Article  PubMed  CAS  Google Scholar 

  45. Eife R, Janka GE, Belohradsky BH, Holtmann H (1989) Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol 6(3):265–272

    Article  PubMed  CAS  Google Scholar 

  46. Imashuku S, Hyakuna N, Funabiki T, Ikuta K, Sako M, Iwai A, Fukushima T, Kataoka S, Yabe M, Muramatsu K, Kohdera U, Nakadate H, Kitazawa K, Toyoda Y, Ishii E (2002) Low natural killer activity and central nervous system disease as a high-risk prognostic indicator in young patients with hemophagocytic lymphohistiocytosis. Cancer 94(11):3023–3031

    Article  PubMed  Google Scholar 

  47. Horne A, Zheng C, Lorenz I, Lofstedt M, Montgomery SM, Janka G, Henter JI, Marion Schneider E (2005) Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistiocytosis provides therapeutic guidance. Br J Haematol 129(5):658–666

    Article  PubMed  Google Scholar 

  48. Imashuku S (2002) Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 44(3):259–272

    Article  PubMed  Google Scholar 

  49. Mischler M, Fleming GM, Shanley TP, Madden L, Levine J, Castle V, Filipovich AH, Cornell TT (2007) Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit. Pediatrics 119(5):e1212–1218

    Article  PubMed  Google Scholar 

  50. Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ (2009) Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer 53(2):184–190

    Article  PubMed  Google Scholar 

  51. Huck K, Feyen O, Niehues T, Ruschendorf F, Hubner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A, Jumaa H, Borkhardt A (2009) Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 119(5):1350–1358

    Article  PubMed  CAS  Google Scholar 

  52. Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, Imai S, Ohga S, Kanegane H, Tsuchiya S, Morio T, Mori M, Yokota S, Imashuku S (2005) Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80(1):64–69

    Article  PubMed  Google Scholar 

  53. Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, Seki H, Igarashi N, Maruhashi K, Katayama K, Katoh E, Terao G, Sakiyama Y, Koizumi S (2001) Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 98(6):1882–1888

    Article  PubMed  CAS  Google Scholar 

  54. Yoshiyama M, Kounami S, Nakayama K, Aoyagi N, Yoshikawa N (2008) Clinical assessment of Mycoplasma pneumoniae-associated hemophagocytic lymphohistiocytosis. Pediatr Int 50(4):432–435

    Article  PubMed  CAS  Google Scholar 

  55. Schwarzmeier JD (2002) A potentially fatal complication of Mycoplasma pneumoniae infection – the hemophagocytic syndrome. Respiration 69(1):14–15

    Article  PubMed  Google Scholar 

  56. Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R (2008) Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis – case report and systematic review. J Infect 56(5):381–388

    Article  PubMed  Google Scholar 

  57. Kontopoulou T, Tsaousis G, Vaidakis E, Fanourgiakis P, Michalakeas E, Trigoni E, Samarkos M (2002) Hemophagocytic syndrome in association with visceral leishmaniasis. Am J Med 113(5):439–440

    Article  PubMed  Google Scholar 

  58. Eliopoulos G, Vaiopoulos G, Kittas C, Fessas P (1992) Tuberculosis associated hemophagocytic syndrome complicated with severe bone marrow failure and disseminated intravascular coagulation. Nouv Rev Fr Hematol 34(3):273–276

    PubMed  CAS  Google Scholar 

  59. Goto S, Aoike I, Shibasaki Y, Morita T, Miyazaki S, Shimizu T, Suzuki M (2001) A successfully treated case of disseminated tuberculosis-associated hemophagocytic syndrome and multiple organ dysfunction syndrome. Am J Kidney Dis 38(4):E19

    Article  PubMed  CAS  Google Scholar 

  60. Imashuku S (2007) Systemic type Epstein-Barr virus-related lymphoproliferative diseases in children and young adults: challenges for pediatric hemato-oncologists and infectious disease specialists. Pediatr Hematol Oncol 24(8):563–568

    Article  PubMed  Google Scholar 

  61. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, Matsuyama T, Morishima T (1999) Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 37(1):132–136

    PubMed  CAS  Google Scholar 

  62. Teramura T, Tabata Y, Yagi T, Morimoto A, Hibi S, Imashuku S (2002) Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma 43(1):173–179

    Article  PubMed  CAS  Google Scholar 

  63. Au WY, Pang A, Choy C, Chim CS, Kwong YL (2004) Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104(1):243–249

    Article  PubMed  CAS  Google Scholar 

  64. Orentas RJ, Rospkopf SJ, Casper JT, Getts RC, Nilsen TW (1999) Detection of Epstein-Barr virus EBER sequence in post-transplant lymphoma patients with DNA dendrimers. J Virol Methods 77(2):153–163

    Article  PubMed  CAS  Google Scholar 

  65. Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, Bacher U (2008) EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 42(3):181–186

    Article  PubMed  CAS  Google Scholar 

  66. Meijer E, Cornelissen JJ (2008) Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 15(6):576–585

    Article  PubMed  Google Scholar 

  67. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F (2009) Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 13(1):54–62

    Article  PubMed  CAS  Google Scholar 

  68. Gross TG (2009) Treatment for Epstein-Barr virus-associated PTLD. Herpes 15(3):64–67

    PubMed  Google Scholar 

  69. O’Sullivan CE, Peng R, Cole KS, Montelaro RC, Sturgeon T, Jenson HB, Ling PD (2002) Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol 67(3):320–326

    Article  PubMed  CAS  Google Scholar 

  70. Bekker V, Scherpbier H, Beld M, Piriou E, van Breda A, Lange J, van Leth F, Jurriaans S, Alders S, Wertheim-van Dillen P, van Baarle D, Kuijpers T (2006) Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents. J Infect Dis 194(9):1323–1330

    Article  PubMed  CAS  Google Scholar 

  71. Padeh S, Sharon N, Schiby G, Rechavi G, Passwell JH (1997) Hodgkin’s lymphoma in ­systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 24(10):2035–2037

    PubMed  CAS  Google Scholar 

  72. Said JW (2007) Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 14(3):189–194

    Article  PubMed  Google Scholar 

  73. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK (2008) Immunodeficiency-associated lymphomas. Blood Rev 22(5):261–281

    Article  PubMed  Google Scholar 

  74. Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Milani R, Bardi A, Minotto C, Agostini P, De Angeli C, Narducci MG, Sabbioni S, Russo G, Negrini M, Castoldi G (2000) Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin’s lymphoma: correlation with clinicobiologic features. J Clin Oncol 18(13):2607–2614

    PubMed  CAS  Google Scholar 

  75. Seidemann K, Henze G, Beck JD, Sauerbrey A, Kuhl J, Mann G, Reiter A (2000) Non-Hodgkin’s lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol 11(Suppl 1):141–145

    Article  PubMed  Google Scholar 

  76. Imashuku S, Miyagawa A, Chiyonobu T, Ishida H, Yoshihara T, Teramura T, Kuriyama K, Imamura T, Hibi S, Morimoto A, Todo S (2002) Epstein-Barr virus-associated T-lymphoproliferative disease with hemophagocytic syndrome, followed by fatal intestinal B lymphoma in a young adult female with WHIM syndrome. Warts, hypogammaglobulinemia, infections, and myelokathexis. Ann Hematol 81(8):470–473

    Article  PubMed  CAS  Google Scholar 

  77. Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, Lebbe C, Kerob D, Dupuy A, Hermine O, Nicolas JF, Latger-Cannard V, Bensoussan D, Bordigoni P, Baleux F, Le Deist F, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F (2005) WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 105(6):2449–2457

    Article  PubMed  CAS  Google Scholar 

  78. Chae KM, Ertle JO, Tharp MD (2001) B-cell lymphoma in a patient with WHIM syndrome. J Am Acad Dermatol 44(1):124–128

    Article  PubMed  CAS  Google Scholar 

  79. Wallet-Faber N, Bodemer C, Blanche S, Delabesse E, Eschard C, Brousse N, Fraitag S (2008) Primary cutaneous Epstein-Barr virus-related lymphoproliferative disorders in 4 immunosuppressed children. J Am Acad Dermatol 58(1):74–80

    Article  PubMed  Google Scholar 

  80. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, Sorensen RU, Notarangelo LD, Modell F (2011) Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res 51(1):61–70

    Article  PubMed  Google Scholar 

  81. Phadke SR, Aggarwal S, Kumari N (2011) The expanding spectrum of Elejalde syndrome: overlap with other disorders of overgrowth. Clin Dysmorphol 20(2):98–101

    Article  PubMed  Google Scholar 

  82. Cahali JB, Fernandez SA, Oliveira ZN, Machado MC, Valente NS, Sotto MN (2004) Elejalde syndrome: report of a case and review of the literature. Pediatr Dermatol 21(4):479–482

    Article  PubMed  Google Scholar 

  83. de Vries E (2006) Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists. Clin Exp Immunol 145(2):204–214

    Article  PubMed  Google Scholar 

  84. Fleisher TA (2007) Evaluation of suspected immunodeficiency. Adv Exp Med Biol 601:291–300

    Article  PubMed  Google Scholar 

  85. Kharkar V, Pande S, Mahajan S, Dwiwedi R, Khopkar U (2007) Griscelli syndrome: a new phenotype with circumscribed pigment loss? Dermatol Online J 13(2):17

    PubMed  Google Scholar 

  86. Rao S, Kar R, Saxena R (2009) Pseudo Chediak-Higashi anomaly in acute myelomonocytic leukemia. Indian J Pathol Microbiol 52(2):255–256

    Article  PubMed  Google Scholar 

  87. Whaley BF (2011) Familial hemophagocytic lymphohistiocytosis in the neonate. Adv Neonatal Care 11(2):101–107

    Article  PubMed  Google Scholar 

  88. Pastural E, Barrat FJ, Dufourcq-Lagelouse R, Certain S, Sanal O, Jabado N, Seger R, Griscelli C, Fischer A, de Basile Saint G (1997) Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet 16(3):289–292

    Article  PubMed  CAS  Google Scholar 

  89. Menasche G, Ho CH, Sanal O, Feldmann J, Tezcan I, Ersoy F, Houdusse A, Fischer A, de Basile Saint G (2003) Griscelli syndrome restricted to hypopigmentation results from a ­melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J Clin Invest 112(3):450–456

    PubMed  CAS  Google Scholar 

  90. Janka G, zur Stadt U. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2005:82–8

    Google Scholar 

  91. Griscelli C, Prunieras M (1978) Pigment dilution and immunodeficiency: a new syndrome. Int J Dermatol 17(10):788–791

    Article  PubMed  CAS  Google Scholar 

  92. Sneller MC, Dale JK, Straus SE (2003) Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 15(4):417–421

    Article  PubMed  CAS  Google Scholar 

  93. Su HC, Lenardo MJ (2008) Genetic defects of apoptosis and primary immunodeficiency. Immunol Allergy Clin North Am 28(2):329–351, ix

    Article  PubMed  Google Scholar 

  94. Carter LB, Procter JL, Dale JK, Straus SE, Cantilena CC (2000) Description of serologic features in autoimmune lymphoproliferative syndrome. Transfusion 40(8):943–948

    Article  PubMed  CAS  Google Scholar 

  95. Campagnoli MF, Garbarini L, Quarello P, Garelli E, Carando A, Baravalle V, Doria A, Biava A, Chiocchetti A, Rosolen A, Dufour C, Dianzani U, Ramenghi U (2006) The broad spectrum of autoimmune lymphoproliferative disease: molecular bases, clinical features and long-term follow-up in 31 patients. Haematologica 91(4):538–541

    PubMed  CAS  Google Scholar 

  96. Su HC, de Oliveira JB, Leonardo MJ (2008) Programmed cell death in lymphocytes. In: Rich RR, Shearer WT, Fleisher TA, Schroeder H, Weyand C, Frew AJ (eds) Clinical immunology: principles and practice, 3rd edn. Mosby, Philadelphia

    Google Scholar 

  97. Puck JM, Rieux-Laucat F, Deist FL, Straus SE (2007) Autoimmune lymphoproliferative syndrome. In: Ochs HD, Smith CID, Puck JM (eds) Primary immunodeficiency diseases, a molecular and genetic approach, 2nd edn. Oxford University Press, New York, pp 326–341

    Google Scholar 

  98. Bleesing JJ, Straus SE, Fleisher TA (2000) Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 47(6):1291–1310

    Article  PubMed  CAS  Google Scholar 

  99. Kasahara Y, Wada T, Niida Y, Yachie A, Seki H, Ishida Y, Sakai T, Koizumi F, Koizumi S, Miyawaki T, Taniguchi N (1998) Novel FAS (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol 10(2):195–202

    Article  PubMed  CAS  Google Scholar 

  100. Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, Danner RL, Barb J, Munson PJ, Puck JM, Dale J, Straus SE, Fleisher TA, Lenardo MJ (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA 104(21):8953–8958

    Article  PubMed  CAS  Google Scholar 

  101. Husebye ES, Perheentupa J, Rautemaa R, Kampe O (2009) Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 265(5):514–529

    Article  PubMed  CAS  Google Scholar 

  102. Kumar PG, Laloraya M, She JX (2002) Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol Metab Clin North Am 31(2):321–338, vi

    Article  PubMed  CAS  Google Scholar 

  103. Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N (2006) Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3(7):e289

    Article  PubMed  CAS  Google Scholar 

  104. Shikama N, Nusspaumer G, Hollander GA (2009) Clearing the AIRE: on the pathophysiological basis of the autoimmune polyendocrinopathy syndrome type-1. Endocrinol Metab Clin North Am 38(2):273–288, vii

    Article  PubMed  CAS  Google Scholar 

  105. Suzuki E, Kobayashi Y, Kawano O, Endo K, Haneda H, Yukiue H, Sasaki H, Yano M, Maeda M, Fujii Y (2008) Expression of AIRE in thymocytes and peripheral lymphocytes. Autoimmunity 41(2):133–139

    Article  PubMed  CAS  Google Scholar 

  106. Rautemaa R, Hietanen J, Niissalo S, Pirinen S, Perheentupa J (2007) Oral and oesophageal squamous cell carcinoma – a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol 43(6):607–613

    Article  PubMed  Google Scholar 

  107. Purtilo DT, Cassel CK, Yang JP, Harper R (1975) X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet 1(7913):935–940

    Article  PubMed  CAS  Google Scholar 

  108. Marodi L, Notarangelo LD (2007) Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 7(11):851–861

    Article  PubMed  CAS  Google Scholar 

  109. Sumegi J, Seemayer TA, Huang D, Davis JR, Morra M, Gross TG, Yin L, Romco G, Klein E, Terhorst C, Lanyi A (2002) A spectrum of mutations in SH2D1A that causes X-linked ­lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma 43(6):1189–1201

    Article  PubMed  CAS  Google Scholar 

  110. Brandau O, Schuster V, Weiss M, Hellebrand H, Fink FM, Kreczy A, Friedrich W, Strahm B, Niemeyer C, Belohradsky BH, Meindl A (1999) Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 8(13):2407–2413

    Article  PubMed  CAS  Google Scholar 

  111. Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, Okano M, Lanyi A, Sumegi J (1995) X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 38(4):471–478

    Article  PubMed  CAS  Google Scholar 

  112. Benoit L, Wang X, Pabst HF, Dutz J, Tan R (2000) Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol 165(7):3549–3553

    PubMed  CAS  Google Scholar 

  113. Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, van Schaik S, Notarangelo L, Geha R, Roncarolo MG, Oettgen H, De Vries JE, Aversa G, Terhorst C (1998) The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395(6701):462–469

    Article  PubMed  CAS  Google Scholar 

  114. Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, Klein G, Seri M, Wakiguchi H, Purtilo DT, Gross TG (2000) Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 96(9):3118–3125

    PubMed  CAS  Google Scholar 

  115. Erdos M, Uzvolgyi E, Nemes Z, Torok O, Rakoczi E, Went-Sumegi N, Sumegi J, Marodi L (2005) Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat 25(5):506

    Article  PubMed  Google Scholar 

  116. Lindsten T, Seeley JK, Ballow M, Sakamoto K, St Onge S, Yetz J, Aman P, Purtilo DT (1982) Immune deficiency in the X-linked lymphoproliferative syndrome. II. Immunoregulatory T cell defects. J Immunol 129(6):2536–2540

    PubMed  CAS  Google Scholar 

  117. Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, Lambert N, Fischer A, de Saint-Basile G, Latour S (2005) Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 201(5):695–701

    Article  PubMed  CAS  Google Scholar 

  118. Yasuda N, Lai PK, Rogers J, Purtlo DT (1991) Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease. Clin Exp Immunol 83(1):10–16

    Article  PubMed  CAS  Google Scholar 

  119. Purtilo DT, Grierson HL, Davis JR, Okano M (1991) The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990. Pediatr Pathol 11(5):685–710

    Article  PubMed  CAS  Google Scholar 

  120. Migliorati R, Castaldo A, Russo S, Porta F, Fiorillo A, Guida S, Poggi V, Guarino A (1994) Treatment of EBV-induced lymphoproliferative disorder with epipodophyllotoxin VP16-213. Acta Paediatr 83(12):1322–1325

    Article  PubMed  CAS  Google Scholar 

  121. Aghamohammadi A, Lougaris V, Plebani A, Miyawaki T, Durandy A, Hammarström L (2008) Predominantly antibody deficiencies. In: Rezaei N, Aghamohammadi A, Notarangelo LD (eds) Primary immunodeficiency diseases. Springer, Berlin/Heidelberg, pp 97–130

    Chapter  Google Scholar 

  122. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, Cahn AP, Durham J, Heath P, Wray P, Pavitt R, Wilkinson J, Leversha M, Huckle E, Shaw-Smith CJ, Dunham A, Rhodes S, Schuster V, Porta G, Yin L, Serafini P, Sylla B, Zollo M, Franco B, Bolino A, Seri M, Lanyi A, Davis JR, Webster D, Harris A, Lenoir G, de Basile St G, Jones A, Behloradsky BH, Achatz H, Murken J, Fassler R, Sumegi J, Romeo G, Vaudin M, Ross MT, Meindl A, Bentley DR (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20(2):129–135

    Article  PubMed  CAS  Google Scholar 

  123. Latour S, Veillette A (2003) Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol Rev 192:212–224

    Article  PubMed  CAS  Google Scholar 

  124. Gilmour KC, Cranston T, Jones A, Davies EG, Goldblatt D, Thrasher A, Kinnon C, Nichols KE, Gaspar HB (2000) Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression. Eur J Immunol 30(6):1691–1697

    Article  PubMed  CAS  Google Scholar 

  125. Shinozaki K, Kanegane H, Matsukura H, Sumazaki R, Tsuchida M, Makita M, Kimoto Y, Kanai R, Tsumura K, Kondoh T, Moriuchi H, Miyawaki T (2002) Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 14(10):1215–1223

    Article  PubMed  CAS  Google Scholar 

  126. Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Basile Saint G, Latour S (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444(7115):110–114

    Article  PubMed  CAS  Google Scholar 

  127. Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ (2009) A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom 76(5):334–344

    PubMed  Google Scholar 

  128. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G (2002) Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100(7):2367–2373

    Article  PubMed  CAS  Google Scholar 

  129. Milone MC, Tsai DE, Hodinka RL, Silverman LB, Malbran A, Wasik MA, Nichols KE (2005) Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105(3):994–996

    Article  PubMed  CAS  Google Scholar 

  130. Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N, Mieli-Vergani G, Pagliuca A, Mufti G, Hadzic N, Davies G, Veys P (2000) Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96(4):1239–1246

    PubMed  CAS  Google Scholar 

  131. Cunningham-Rundles C, Bodian C (1999) Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92(1):34–48

    Article  PubMed  CAS  Google Scholar 

  132. Howie D, Sayos J, Terhorst C, Morra M (2000) The gene defective in X-linked lymphoproliferative disease controls T cell dependent immune surveillance against Epstein-Barr virus. Curr Opin Immunol 12(4):474–478

    Article  PubMed  CAS  Google Scholar 

  133. Aghamohammadi A, Kanegane H, Moein M, Farhoudi A, Pourpak Z, Movahedi M, Gharagozlou M, Zargar AA, Miyawaki T (2003) Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency. Int J Hematol 78(1):45–47

    Article  PubMed  CAS  Google Scholar 

  134. Soresina A, Lougaris V, Giliani S, Cardinale F, Armenio L, Cattalini M, Notarangelo LD, Plebani A (2002) Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency. Eur J Pediatr 161(12):656–659

    Article  PubMed  CAS  Google Scholar 

  135. Engel P, Eck MJ, Terhorst C (2003) The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 3(10):813–821

    Article  PubMed  CAS  Google Scholar 

  136. Mroczek EC, Weisenburger DD, Grierson HL, Markin R, Purtilo DT (1987) Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med 111(6):530–535

    PubMed  CAS  Google Scholar 

  137. Hugle B, Suchowerskyj P, Hellebrand H, Adler B, Borte M, Sack U, Overberg-Schmidt US, Strnad N, Otto J, Meindl A, Schuster V (2004) Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease – report of three cases. J Clin Immunol 24(5):515–522

    Article  PubMed  CAS  Google Scholar 

  138. Harrington DS, Weisenburger DD, Purtilo DT (1987) Malignant lymphoma in the X-linked lymphoproliferative syndrome. Cancer 59(8):1419–1429

    Article  PubMed  CAS  Google Scholar 

  139. Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ (2002) X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br J Haematol 119(3):585–595

    Article  PubMed  CAS  Google Scholar 

  140. Dutz JP, Benoit L, Wang X, Demetrick DJ, Junker A, de Sa D, Tan R (2001) Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood 97(1):95–100

    Article  PubMed  CAS  Google Scholar 

  141. Yin L, Ferrand V, Lavoue MF, Hayoz D, Philippe N, Souillet G, Seri M, Giacchino R, Castagnola E, Hodgson S, Sylla BS, Romeo G (1999) SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet 105(5):501–505

    Article  PubMed  CAS  Google Scholar 

  142. Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R (2005) Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J Immunol 174(6):3153–3157

    PubMed  CAS  Google Scholar 

  143. Purtilo DT (1986) Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients. AIDS Res 2(Suppl 1):S177–181

    PubMed  Google Scholar 

  144. Schwartzberg PL, Mueller KL, Qi H, Cannons JL (2009) SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 9(1):39–46

    Article  PubMed  CAS  Google Scholar 

  145. Ferguson PJ, Blanton SH, Saulsbury FT, McDuffie MJ, Lemahieu V, Gastier JM, Francke U, Borowitz SM, Sutphen JL, Kelly TE (2000) Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. Am J Med Genet 90(5):390–397

    Article  PubMed  CAS  Google Scholar 

  146. Slatter MA, Bhattacharya A, Abinun M, Flood TJ, Cant AJ, Gennery AR (2005) Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant 35(7):683–689

    Article  PubMed  CAS  Google Scholar 

  147. Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE (1993) Correction of Duncan’s syndrome by allogeneic bone marrow transplantation. Lancet 342(8871):587–588

    Article  PubMed  CAS  Google Scholar 

  148. Ziegner UH, Ochs HD, Schanen C, Feig SA, Seyama K, Futatani T, Gross T, Wakim M, Roberts RL, Rawlings DJ, Dovat S, Fraser JK, Stiehm ER (2001) Unrelated umbilical cord stem cell transplantation for X-linked immunodeficiencies. J Pediatr 138(4):570–573

    Article  PubMed  CAS  Google Scholar 

  149. Gross TG, Filipovich AH, Conley ME, Pracher E, Schmiegelow K, Verdirame JD, Vowels M, Williams LL, Seemayer TA (1996) Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant 17(5):741–744

    PubMed  CAS  Google Scholar 

  150. Ochs HD, Oukka M, Torgerson TR (2009) TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 123(5):977–983, quiz 984–985

    Article  PubMed  CAS  Google Scholar 

  151. Chatila TA (2005) Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116(5):949–959, quiz 960

    Article  PubMed  CAS  Google Scholar 

  152. Torgerson TR, Linane A, Moes N, Anover S, Mateo V, Rieux-Laucat F, Hermine O, Vijay S, Gambineri E, Cerf-Bensussan N, Fischer A, Ochs HD, Goulet O, Ruemmele FM (2007) Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology 132(5):1705–1717

    Article  PubMed  CAS  Google Scholar 

  153. Wildin RS, Smyk-Pearson S, Filipovich AH (2002) Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 39(8):537–545

    Article  PubMed  CAS  Google Scholar 

  154. Halabi-Tawil M, Ruemmele FM, Fraitag S, Rieux-Laucat F, Neven B, Brousse N, De Prost Y, Fischer A, Goulet O, Bodemer C (2009) Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br J Dermatol 160(3):645–651

    Article  PubMed  CAS  Google Scholar 

  155. Gambineri E, Torgerson TR, Ochs HD (2003) Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 15(4):430–435

    Article  PubMed  CAS  Google Scholar 

  156. De Benedetti F, Insalaco A, Diamanti A, Cortis E, Muratori F, Lamioni A, Carsetti R, Cusano R, De Vito R, Perroni L, Gambarara M, Castro M, Bottazzo GF, Ugazio AG (2006) Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome. Clin Gastroenterol Hepatol 4(5):653–659

    Article  PubMed  CAS  Google Scholar 

  157. Wildin RS, Freitas A (2005) IPEX and FOXP3: clinical and research perspectives. J Autoimmun 25(Suppl):56–62

    Article  PubMed  CAS  Google Scholar 

  158. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM (2000) JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 106(12):R75–81

    Article  PubMed  CAS  Google Scholar 

  159. Lucas KG, Ungar D, Comito M, Bayerl M, Groh B (2007) Submyeloablative cord blood transplantation corrects clinical defects seen in IPEX syndrome. Bone Marrow Transplant 39(1):55–56

    Article  PubMed  CAS  Google Scholar 

  160. Ozcan E, Notarangelo LD, Geha RS (2008) Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 122(6):1054–1062, quiz 1063–1064

    Article  PubMed  CAS  Google Scholar 

  161. Whitelaw DA, Gopal R, Freeman V (2005) Survival of patients with SLE admitted to an intensive care unit-a retrospective study. Clin Rheumatol 24(3):223–227

    Article  PubMed  CAS  Google Scholar 

  162. Zandman-Goddard G, Shoenfeld Y (2005) Infections and SLE. Autoimmunity 38(7):473–485

    Article  PubMed  CAS  Google Scholar 

  163. Chou NK, Ko WJ, Chi NH, Chen YS, Yu HY, Hsu RB, Fang CT, Chang SC, Lin FY, Chu SH, Wang SS (2006) Sparing immunosuppression in heart transplant recipients with severe sepsis. Transplant Proc 38(7):2145–2146

    Article  PubMed  CAS  Google Scholar 

  164. Taylor JL, Palmer SM (2006) Critical care perspective on immunotherapy in lung transplantation. J Intensive Care Med 21(6):327–344

    Article  PubMed  Google Scholar 

  165. Taddio A, Faleschini E, Valencic E, Granzotto M, Tommasini A, Lepore L, Andolina M, Barbi E, Ventura A (2007) Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. Eur J Pediatr 166(11):1195–1197

    Article  PubMed  Google Scholar 

  166. Kobayashi I, Nakanishi M, Okano M, Sakiyama Y, Matsumoto S (1995) Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. Eur J Pediatr 154(7):594–595

    Article  PubMed  CAS  Google Scholar 

  167. Baud O, Goulet O, Canioni D, Le Deist F, Radford I, Rieu D, Dupuis-Girod S, Cerf-Bensussan N, Cavazzana-Calvo M, Brousse N, Fischer A, Casanova JL (2001) Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 344(23):1758–1762

    Article  PubMed  CAS  Google Scholar 

  168. Mazzolari E, Forino C, Fontana M, D’Ippolito C, Lanfranchi A, Gambineri E, Ochs H, Badolato R, Notarangelo LD (2005) A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant 35(10):1033–1034

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatrics, Takasago-seibu Hospital, Takasago, Japan

    Shinsaku Imashuku M.D., Ph.D.

  2. Department of Infectious and Pediatric Immunology, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary

    Melinda Erdős M.D., Ph.D. & László Maródi M.D., Ph.D., D.Sc.

  3. Department of Pediatrics, Kuwait University, Kuwait, Kuwait

    Waleed Al-Herz M.D.

  4. Department of Allergy and Clinical Immunology, Yazd University of Medical Sciences, Yazd, Iran

    Mohammad Hassan Bemanian M.D.

  5. Department of Pediatrics, Graduate School of Medicine and Pharmaceutical, University of Toyama, Toyama, Japan

    Hirokazu Kanegane M.D., Ph.D.

  6. Department of Pediatrics, Research Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran

    Payam Mohammadinejad M.D.

  7. Primary Immunodeficiency Clinic, Laboratory of Host Defenses, NIAID, National Institute of Health, Bethesda, MD, USA

    Sergio D. Rosenzweig M.D., Ph.D.

  8. Division of Clinical Immunology and Allergy, Research Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran

    Asghar Aghamohammadi M.D., Ph.D.

Authors
  1. Shinsaku Imashuku M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melinda Erdős M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Waleed Al-Herz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Hassan Bemanian M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirokazu Kanegane M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. László Maródi M.D., Ph.D., D.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Payam Mohammadinejad M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sergio D. Rosenzweig M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Asghar Aghamohammadi M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Research Center for Immunodeficiencies, Children's Medical Center Hospital, Tehran University of Medical Sciences, Qarib St, Keshavarz Blvd, Tehran, 14194, Iran

    Asghar Aghamohammadi

  2. Research Center for Immunodeficiencies, Children's Medical Center Hospital, Tehran University of Medical Sciences, Qarib St, Keshavarz Blvd, Tehran, 14194, Iran

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Imashuku, S. et al. (2012). Immune Dysregulation Diseases. In: Aghamohammadi, A., Rezaei, N. (eds) Clinical Cases in Primary Immunodeficiency Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-31785-9_5

Download citation

Publish with us

Policies and ethics

Search

Navigation